RXI Pharmaceuticals Corp (NASDAQ:RXII): At the American Academy of Dermatology (AAD) Summer Meeting, data from a pilot study of Samcyprone (diphenylcyclopropenone ointment) in the treatment of common warts was presented. Overall, 38.1% of subjects saw a greater than 50% clearance over seven weeks compared to 6.7% in the placebo arm (p=0.051). On a per-protocol basis, 47.6% saw greater than 50% clearance (p=0.011). A Phase IIa with an improved formulation and 10-week treatment period was initiated in December 2015, with enrolment expected to be completed by year-end 2016.
Increased confidence following data
Diphenylcyclopropenone (DPCP) has been used for decades as a compounded drug, though never FDA approved, with no standardized formulation or regimen and little clinical data. The presentation at AAD provides some much needed clarity on the effect size for the product and increases our confidence that Samcyprone will be useful for dermatologists given that up to a third of warts are considered recalcitrant.
To read the entire report Please click on the pdf File Below